Clinical Differentiation Becomes Operational Reality

Lucid MS targets neuroprotection without immunomodulation. That scientific angle now matches an operational plan, with an oral product for Phase 2 produced by a proven CDMO. MS patients and investigators tend to favor simpler dosing that does not add immunosuppression risk. That helps recruitment and retention, which improves the chance of a readable effect on PET MRI. Safety is already in the bag. IND is next. Execution like this often draws partner interest because it de risks both the science and the schedule. Pricing still lags that reality. The chart says 26.00 and 28.00 are the near gates to clear UPD cleared, 29 now